Russia’s Sputnik V vaccine shot against COVID-19 is proven to be around 83 per cent effective against the Delta variant of coronavirus, Russian Direct Investment Fund (RDIF) said on Wednesday quoting data collected by the health ministry.
The RDIF statement said, “The data confirms that Sputnik V remains protective against newly detected variants and retains one of the best safety and efficacy parameters. The Russian Ministry of Health has also published data on Sputnik V’s efficacy against the Delta variant. The vaccine is 83.1 per cent effective and shows 6x reduction of infection risk. Sputnik V is also 94.4 per cent effective against hospitalizations with 18x reduction in hospitalisation risk.”
Currently, in 69 countries Sputnik V vaccine has been approved for a total population exceeding 3.7 billion people – nearly half of the global population. The Russian vaccine has been found to be the best vaccine in all efficacy parameters in various countries where multiple vaccines are already used. Moreover, real-world data found during mass vaccinations in Argentina, Bahrain, Hungary, Mexico, Russia, Serbia, the Philippines and UAE demonstrate lack of serious contrary events (such as CVTs or myocarditis).
It has been concluded by RDIF that production partnerships with more than 20 companies in 14 countries, including the leading manufacturers in India, China, South Korea, Argentina, Mexico and other countries.
The statement released by RDIF also mentioned that the two-dose Sputnik V vaccine, the single dose Sputnik Light vaccine is also demonstrating high safety and efficacy results in Argentina. Sputnik Light is the first component of Sputnik V (recombinant human adenovirus serotype number 26 (rAd26)). Sputnik Light had helped to cause antibodies in 94 per cent of those vaccinated and provided for a strong immune response showed the data from the Ministry of Health of the province of Buenos Aires.